The T-cell Immunotherapies Market is Projected to Reach USD 26 Billion by 2030, Growing at an Annualized Rate of 41.5%, Claims Roots Analysis
Adaptimmune Therapeutics plc - American Depositary Shares (ADAP)
Last adaptimmune therapeutics plc - american depositary shares earnings: 5/9 07:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.adaptimmune.com/phoenix.zhtml?c=253991&p=irol-newsarticle&id=2255800
Company Research
Source: PR Newswire
LONDON, Aug. 1, 2019 /PRNewswire/ -- Roots Analysis has announced the addition of "Global T-Cell (CAR-T, TCR, and TIL) Therapy Market (4th Edition), 2019 – 2030" report to its list of offerings. Encouraging clinical results reported across trials of various hematological cancers and solid tumors have inspired research groups to focus their efforts on the development of this relatively novel class of immunotherapies. With two approved therapies, namely KYMRIAH® (Novartis) and YESCARTA® (Gilead Sciences), the T-cell immunotherapy pipeline has evolved significantly over the past few years. Of these, certain pipeline candidates have also entered mid to late-stage (phase II and above) trials and are anticipated to enter the market over the next 5-10 years. To order this 800+ page report, which features 210+ figures and 355+ tables, please visit this link Key Market Insights Close to 650+ candidate therapies in the development pipelineCAR-T cell products continue to dominate the clinical /
Show less
Read more
Impact Snapshot
Event Time:
ADAP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ADAP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ADAP alerts
High impacting Adaptimmune Therapeutics plc - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
ADAP
News
- Adaptimmune to Participate in Scientific and Medical Conferences this November and December [Yahoo! Finance]Yahoo! Finance
- OTC Markets Hosts Virtual Investor Presentation with Adrian Rawcliffe, CEO of Adaptimmune Therapeutics, and Michael Kim, Senior Analyst at Zacks SCR [Yahoo! Finance]Yahoo! Finance
- Immuno-Oncology 360º Announces 2025 Keynotes and Featured Speakers for the 11th Annual Meeting in BostonPR Web
- ReCode Announces Two Key Additions to Scientific Advisory BoardBusiness Wire
- Adaptimmune Therapeutics plc's (NASDAQ:ADAP) top owners are individual investors with 39% stake, while 28% is held by institutions [Yahoo! Finance]Yahoo! Finance
ADAP
Analyst Actions
- 8/13/24 - HC Wainwright
ADAP
Sec Filings
- 11/1/24 - Form 8-K
- 9/23/24 - Form 8-K
- 8/12/24 - Form 10-Q
- ADAP's page on the SEC website